Spinal meningiomas arise from arachnoid cap cells (meningothelial cells) of the spinal meninges. They are among the most common primary intradural extramedullary tumours of the spinal canal and account for approximately one quarter of spinal tumours.
According to the WHO Classification of Tumours of the Central Nervous System, meningiomas are assigned to three histopathological grades:
Spinal meningiomas typically grow slowly and may therefore remain clinically silent for a prolonged period. Neurological symptoms develop primarily as a consequence of progressive compression of the spinal cord and, less commonly, adjacent nerve roots.
Computed tomography is particularly useful for demonstrating intratumoral calcification and assessing associated osseous anatomy.
CT myelography may serve as an alternative in patients in whom MRI is contraindicated or cannot be performed.
Definitive histopathological diagnosis is generally obtained following surgical resection or biopsy. There are no specific circulating tumour markers for spinal meningioma.
Management of spinal meningioma is individualised according to neurological symptoms, tumour size, anatomical location, growth behaviour, WHO grade, patient age, comorbidities, and previous treatment. Depending on the clinical situation, the following strategies may be used alone or in combination.
„Watch and Wait (Active Surveillance)“
Stereotactic Radiosurgery and Radiotherapy have an increasingly established role in the management of selected spinal meningiomas, particularly for residual disease following subtotal resection and for recurrent tumours.
The high spatial precision of the CyberKnife system allows highly conformal treatment of lesions in challenging anatomical locations, including ventral or ventrolateral tumours in close proximity to the spinal cord, while rigorously limiting radiation exposure to the spinal cord and adjacent neural structures.
CyberKnife uses robotically guided, non-isocentric, multi-directional beam delivery to achieve highly conformal dose distributions tailored to the three-dimensional geometry of the meningioma. Target-volume delineation is based on high-resolution contrast-enhanced MRI and planning CT. Dural involvement, including a radiographically evident dural tail where clinically appropriate, is assessed individually during treatment planning. Critical structures—most importantly the spinal cord, nerve roots, and other adjacent neural tissues—are precisely contoured, and established dose constraints are rigorously respected.
No. Small, asymptomatic spinal meningiomas without significant spinal cord compression may initially be managed with serial MRI surveillance. Treatment becomes appropriate when radiographic growth, progressive myelopathy, or other neurological symptoms develop. In patients with an increased operative risk or surgically challenging anatomy, stereotactic radiosurgery or radiotherapy may provide an effective non-invasive treatment alternative in appropriately selected cases.
Both arise from meningothelial cells, but they differ in anatomical location, clinical presentation, and therapeutic approach. Spinal meningiomas occur predominantly in the thoracic spine, show a particularly marked female predominance, and typically present with symptoms of progressive spinal cord compression and myelopathy. Intracranial meningiomas arise along the cranial dura—for example at the skull base or cerebral convexity—and may present with headache, seizures, cranial neuropathies, or focal neurological deficits depending on their location.
Yes. Recurrent spinal meningioma after surgery may be treated with CyberKnife® stereotactic radiotherapy without the need for repeat open surgery in appropriately selected patients. Re-irradiation after previous radiotherapy may also be feasible in selected cases, but requires meticulous reconstruction of the previous dose distribution and strict consideration of the cumulative spinal cord dose and other organ-at-risk constraints. Such decisions are made individually within the multidisciplinary tumor board.
Spinal meningiomas occur approximately three to four times more frequently in women than in men. Hormonal influences are considered biologically relevant because many meningiomas express progesterone receptors and, less consistently, estrogen receptors. Associations with exogenous hormonal exposure and pregnancy have been investigated, although the clinical significance varies according to tumor biology and individual circumstances.
Following complete microsurgical resection of a WHO grade 1 spinal meningioma, long-term recurrence rates are generally low. The risk increases when only subtotal resection is feasible, particularly in tumors with a ventral attachment, extensive dural involvement, or adherence to critical neural structures. WHO grade 2 meningiomas have a higher intrinsic recurrence risk. In selected patients with residual or recurrent disease, postoperative stereotactic radiosurgery or radiotherapy may improve durable local tumor control.
Request a no-obligation review of your medical reports by our medical team.